SK Investment

SK Investment is the corporate vehicle of South Korea’s SK Group, driving global investments to upgrade existing business models via strategic pharmaceutical manufacturing and logistics scaling. Operating from Seoul, the corporate investor focuses on pharma/therapeutics, biotech, and life sciences tools where strategic alignment with SK’s broader industrial and healthcare ambitions creates leverage. The mandate blends financial return with strategic positioning across SK’s evolving healthcare and life sciences franchises.

SK Investment participates at Series B, Series C, and Growth stages, with checks of $5M to $25M, typically as part of syndicates led by specialist healthcare investors. Geographic focus spans Korea, the US, and Europe, reflecting SK’s global industrial footprint and the parent group’s interest in transpacific life sciences opportunities.

Founders should approach SK Investment as a strategic partner where corporate alignment matters as much as financial terms. Expect parallel discussions about manufacturing, distribution, or commercial partnership in Korea and Asia alongside the funding round. Limited public information is available on specific portfolio companies given the corporate structure, so engagement typically comes through existing co-investors, sector bankers, or direct corporate development outreach with a clear strategic rationale prepared upfront.